The Safety of available immunotherapy for the treatment of glioblastoma
Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH. The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opinion On Drug Safety 2017, 16: 277-287. PMID: 27989218, PMCID: PMC5404815, DOI: 10.1080/14740338.2017.1273898.Peer-Reviewed Original ResearchConceptsClinical trialsCurrent immunotherapiesCommon malignant primary brain tumorMalignant primary brain tumorAdoptive T-cell immunotherapyReviewed clinical trialsRole of immunotherapyImmune checkpoint blockadeMaximal surgical resectionOngoing clinical trialsPrimary brain tumorsT-cell immunotherapyTreatment of glioblastomaAdjuvant chemoradiationAvailable immunotherapiesCheckpoint blockadeCytokine therapySurgical resectionImmunotherapeutic approachesCell immunotherapyPatient survivalRecurrent glioblastomaVaccination strategiesSafety dataBrain tumors